



INDEPENDENT AUDITOR'S REPORT

To the Members
Vegil labs Private Limited

Report on the Audit of Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **Vegil labs Private Limited** (hereinafter referred to as the Holding Company), its Joint ventures together referred to as the Group), which comprise the Consolidated Balance sheet as at 31 March 2024, and the consolidated Statement of Profit and Loss (including other comprehensive income), consolidated Statement of changes in equity and consolidated statement of Cash Flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports on separate financial statements / consolidated financial statements and on the other financial information of the joint venture, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Act, of the consolidated state of affairs (consolidated financial position) of the Group as at 31 March 2024, and its consolidated profits (consolidated financial performance including other comprehensive profits), its consolidated cash flows and the consolidated changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters paragraph below is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement and based on the consideration of separate financial statements / consolidated financial statements and on the other financial information of the joint venture entities, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

There are no key audit matters as per SA 701, that were observed by us during the course of audit.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

Information Other than the Consolidated Financial Statements and Auditors' Report Thereon

The Holding Company's Management and Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the consolidated financial statements and our auditor's report thereon, and the remaining sections of the Company's Annual Report, which are expected to be made available to us after that date.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Management and Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated state of affairs (consolidated financial position), consolidated profit or loss (consolidated financial performance including other comprehensive income), consolidated changes in equity and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Ind AS specified under Section 133 of the Act. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of consolidated financial statements. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, companies covered under the Act are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial statements have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid

In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.



Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to express an opinion on the consolidated financial statements, of which we are the independent auditors. We are responsible for the direction, supervision and performance of the audit of financial information of such entities. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results

We believe that the audit evidence obtained by us along, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by section 143(3) of the Companies Act, we report, to the extent applicable, that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in paragraph 2(f) below on reporting under rule 11(g);
 - c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including other comprehensive income, the Consolidated Cash Flow Statement and Consolidated Statement of changes in equity dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - d. In our opinion, the aforesaid consolidated financial statements comply with the Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act read with relevant rules issued there under and other accounting principles generally accepted in India,
 - e. On the basis of written representations received from the directors of the Holding Company as on 31st March, 2024 taken on record by the Board of Directors of the Holding Company and Joint venture, none of the directors of the Group companies incorporated in India are disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Companies Act;



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

- f. Since the Company's turnover as per the last audited financial statements is less than Rs.50 Crores and its borrowing from banks or financial institutions or any Body Corporate at any time during the year is less than Rs.25 Crores, the Company is exempted from getting report of the auditor with respect to existence of internal financial controls with reference to financial statements of the company and its operating effectiveness of such controls, vide notification dated 13 June 2017.

With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- a) The Consolidated financial statements disclose the impact of pending litigations if any, on the consolidated financial position of the group.
- b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company and its joint venture entities.
- d) (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(is), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(is), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- e) The Holding Company has not paid any dividend during the year.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

- f) Based on our examination, which included test checks, the group has used accounting software for maintaining its books of account for the financial year ended March 31, 2024 and
- i. In respect of the Holding company & one of its joint ventures, the companies have used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility. However, the accounting software did not have the audit trail feature enabled throughout the year.
 - ii. In respect of 01 Joint venture, since it is an entity formed under Limited Liability Partnership Act, 2008, provisions of the audit trail are not applicable to it.
2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Holding Company and its Joint venture included in the consolidated financial statements of the Holding Company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.

For Bohara Bhandari Bung And Associates LLP
Chartered Accountants
(Firm's Regn No.008127S/S200013)

Sd/-

CA. Yogesh R Bung
Partner
Membership No. 143932

Place: Raichur
Date: 22.05.2024

UDIN: 24143932BKAEOP3914

Vegil Labs Private Limited

Part - I - Consolidated Balance Sheet

(All amounts are in Indian Rupees unless otherwise stated)

| Particulars | Note | As at | As at |
|--------------------------------------|------|--------------------|--------------------|
| | | 31.03.2024 | 31.03.2023 |
| | | Audited | Audited |
| ASSETS | | | |
| Non Current Assets | | | |
| Financial assets | | | |
| (a) Investments | 2 | 59,688,149 | 102,365,833 |
| (b) Loans | 3 | 65,059,072 | - |
| (c) Other Financials Assets | 4 | 702,421 | - |
| (d) Other non Current Asset | 5 | 78,047 | - |
| (e) Deferred Tax Assets | 6 | 1,408,050 | |
| Total Non Current Assets | | 126,935,739 | 102,365,833 |
| Current Assets | | | |
| a) Financial Assets : | | | |
| i) Cash and Cash equivalents | 7 | 66,920 | 27,116 |
| Total Current Assets | | 66,920 | 27,116 |
| Total | | 127,002,659 | 102,392,949 |
| EQUITY AND LIABILITIES | | | |
| Equity: | | | |
| a) Equity Share Capital | 8 | 95,100,000 | 95,100,000 |
| b) Other Equity | 9 | 31,610,486 | (22,390,693) |
| Total Equity | | 126,710,486 | 72,709,307 |
| Liabilities | | | |
| Non Current Liabilities | | | |
| a) Financial Liabilities : | | | |
| i) Borrowings | 10 | - | 28,025,000 |
| b) Other financial liabilities | 11 | - | 916,373 |
| c) Deferred Tax Liabilities | 6 | - | 622,450 |
| Total Non Current Liabilities | | - | 29,563,823 |
| Current Liabilities | | | |
| a) Other Current Liability | 12 | 229,173 | 101,819 |
| a) Provisions | 13 | 63,000 | 18,000 |
| Total Current Liabilities | | 292,173 | 119,819 |
| Total | | 127,002,659 | 102,392,949 |

The accompanying notes form an integral part of the financial statements

As per our Report of even dated
For Bohara Bhandari Bung and Associates LLP
Chartered Accountants
 Firm Regn No. 008127S/S200013

For and on behalf of the Board of Directors
of Vegil Labs Private Limited

Sd/-

CA. Yogesh R.Bung
 Partner
 M.No. 143932

Place : Raichur
 Date : 22/05/2024

Sd/-

Vishnukanth Bhutada
 DIN No.01243391
 Director

Place : Raichur
 Date : 22/05/2024

Sd/-

Ramakant Innani
 DIN No.03222748
 Director

Vegil Labs Private Limited

Part - II - Consolidated Statement of Profit and Loss

(All amounts in Indian Rupees except share data & per share data unless otherwise stated)

| Particulars | Note | For the Year ended 31.03.2024 | For the Year ended 31.03.2023 |
|---|------|----------------------------------|----------------------------------|
| | | Audited | Audited |
| Income | | | |
| a) Other Income | 14 | 7,222,288 | 3,454,557 |
| Total Income | | 7,222,288 | 3,454,557 |
| Expenses | | | |
| a) Finance Cost | 15 | 2,221,728 | 1,018,192 |
| b) Other Expenses | 16 | 85,377 | 42,325 |
| Total Expenses | | 2,307,105 | 1,060,517 |
| Profit / (Loss) before exceptional items and tax | | 4,915,183 | 2,394,040 |
| Share of Profit/(Loss) in Associates | | (18,174,846) | (23,165,759) |
| Profit before Exceptional items | | (13,259,663) | (20,771,719) |
| Exceptional Income / (Expense) | | 66,611,793 | - |
| Profit / (Loss) before tax | | 53,352,130 | (20,771,719) |
| Tax expense | | | |
| 1. Current Income tax | | - | - |
| 2. Deferred tax (Net) | | (649,049) | 622,450 |
| Profit / (Loss) for the year | | 54,001,180 | (21,394,169) |
| Other Comprehensive Income | | | - |
| Total Comprehensive Income | | 54,001,180 | (21,394,169) |
| Earning per equity share for Rs.10/- face value (Continued Operations) | | | |
| Basic | 18 | 5.68 | (2.25) |
| Diluted | | 5.68 | (2.25) |
| Number of shares used in computing earnings per share (Continued Operations)(Weighted Average) | | | |
| Basic | | 9,510,000 | 9,510,000 |
| Diluted | | 9,510,000 | 9,510,000 |

The accompanying notes form an integral part of the financial statements

As per our Report of even dated
For Bohara Bhandari Bung and Associates LLP
Chartered Accountants
 Firm Regn No. 008127S/S200013

**For and on behalf of the Board of Directors of
 Vegil Labs Private Limited**

Sd/-

Sd/-

Sd/-

CA. Yogesh R.Bung
 Partner
 M.No. 143932

Vishnukanth Bhutada
 DIN No.01243391
 Director

Ramakant Innani
 DIN No.03222748
 Director

Place : Raichur
 Date : 22/05/2024

Place : Raichur
 Date : 22/05/2024

Vegil Labs Private Limited

Consolidated Statement of Cash Flows

(All amounts are in Indian Rupees unless otherwise stated)

| Particulars | For the year ended 31.03.2024 | For the year ended 31.03.2023 |
|--|----------------------------------|----------------------------------|
| <u>CASH FLOW FROM OPERATING ACTIVITIES</u> | | |
| Profit before Tax | 53,352,130 | 1,397,516 |
| Add/Less: Adjustments | | |
| Finance Cost | 2,221,728 | 1,018,192 |
| Interest Income | (1,780,468) | - |
| Notional Interest Income | (5,441,820) | (3,454,557) |
| Share of (profit)/loss from Joint ventures & Associates | 18,174,846 | - |
| Profit on sale of investments | (66,611,793) | - |
| Operating profit before working capital changes & Other Adjustments | (85,377) | (1,038,849) |
| <u>Adjustments for Increase / (Decrease) in Operating Liabilities</u> | | |
| - Short Term Provisions | 45,000 | 18,000 |
| - Other Financial Liabilities | (789,019) | 916,373 |
| - Other Current Liabilities | - | 101,819 |
| | (829,396) | (2,657) |
| Less: Income Taxes (Net) | (78,047) | - |
| Net Cash flow from Operating activities | (907,443) | (2,657) |
| <u>CASH FLOWS FROM INVESTING ACTIVITIES</u> | | |
| Purchase of Investments | (14,825,000) | (122,077,035) |
| Sale of Investments | 110,000,000 | - |
| Loan given to parent company | (65,059,072) | - |
| Interest Income | 1,078,047 | - |
| Net cash outflow from Investing Activities | 31,193,975 | (122,077,035) |
| <u>CASH FLOWS FROM FINANCING ACTIVITIES</u> | | |
| Proceeds from issue of Share Capital | - | 95,100,000 |
| Proceeds from/ (repayments) Long term borrowings (Net) | (28,025,000) | 28,025,000 |
| Finance Cost | (2,221,728) | (1,018,192) |
| Net Cash earned from Financing Activities | (30,246,728) | 122,106,808 |
| Net Increase/(decrease)in Cash and Cash Equivalents | 39,804 | (95,072,311) |
| Cash & Cash Equivalents at the Beginning of the year | 27,116 | 95,099,427 |
| Cash & Cash Equivalents at the end of the year | 66,920 | 27,116 |

| Components of Cash and Cash Equivalents | For the year ended 31.03.2024 | For the year ended 31.03.2023 |
|---|----------------------------------|----------------------------------|
| Cash in Hand | - | - |
| Cash at Banks | 66,920 | 27,116 |
| Total Cash and Cash Equivalents | 66,920 | 27,116 |

Reconciliation between opening and closing balances for liabilities arising from financing activities

| Particulars | As at April 01, 2023 | Cash flows | Non cash movement | As at March 31, 2024 |
|-------------------------|-------------------------|--------------|----------------------|-------------------------|
| Non- current borrowings | 28,025,000 | (28,025,000) | - | - |

Note:

1. The Cash Flow Statement has been prepared under the "Indirect Method" as set out in Ind AS 7, 'Statement of Cash Flows' as prescribed under Companies (Accounting Standard) Rules, 2015.

The accompanying significant accounting policies and notes form an integral part of the financial statements.

As per our Report of even dated
for **Bohara Bhandari Bung And Associates LI**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

For and on behalf of the Board of Directors of
Vegil Labs Private Limited

Sd/-

CA. Yogesh R Bung
Partner
M.No.143932

Place : Raichur
Date : 22/05/2024

Sd/-

Vishnukanth Bhutada
DIN No.01243391
Director

Place : Raichur
Date : 22/05/2024

Sd/-

Ramakant Innani
DIN No.03222748
Director

Vegil Labs Private Limited**Statement of Changes in Equity for the year ended 31.03.2024***(All amounts are in Indian Rupees in lakhs Except Shares data and per Share data, unless otherwise stated)***4 A) Equity Share Capital**

| Particulars | 31.03.2024 | 31.03.2023 |
|---|-------------------|-------------------|
| Balance at the beginning of the Reporting period | 95,100,000 | 95,100,000 |
| Changes in Equity Share Capital due to prior period errors | - | - |
| Restated balance at the beginning of the current reporting period | 95,100,000 | 95,100,000 |
| Changes in equity share capital during the current year | - | - |
| Changes in equity share capital during the year | - | - |
| Balance at the end of the reporting period | 95,100,000 | 95,100,000 |

B) Other Equity

| Particulars | Reserves and Surplus | For the Period 31.03.2024 | For the Period 31.03.2023 |
|---|----------------------|---------------------------|---------------------------|
| | Retained Earnings | | |
| Balance at the beginning of the current reporting period | (22,390,693) | (22,390,693) | (996,524) |
| Changes during the period | 54,001,180 | 54,001,180 | (21,394,169) |
| Restated balance at the beginning of the reporting period | 31,610,486 | 31,610,486 | - |
| Total Comprehensive income for the year | - | - | - |
| Dividends | - | - | - |
| Transfer to retained earning | - | - | - |
| Balance at the end of the reporting period | 31,610,486 | 31,610,486 | (22,390,693) |

Notes:

Retained Earnings: This Reserve represents the cumulative profits of the Company. This Reserve can be utilised in accordance with the provisions of the Companies Act, 2013.

The accompanying significant accounting policies and notes form an integral part of the financial statements.

As per our Report of even dated

For Bohara Bhandari Bung and Associates LLP
Chartered Accountants

Firm Regn No. 008127S/S200013

For and on behalf of the Board of Directors of
Vegil Labs Private Limited

Sd/-

CA. Yogesh R.Bung

Partner
M.No. 143932

Place : Raichur
Date : 22/05/2024

Sd/-

Vishnukanth Bhutada

DIN No.01243391
Director

Place : Raichur
Date : 22/05/2024

Sd/-

Ramakant Innani

DIN No.03222748
Director

Vegil Labs Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

Equity Share Capital

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|---------------------|---------------------|
| Authorised | | |
| Equity shares | | |
| 1,00,00,000 Shares of Rs. 10/- each par value | 100,000,000 | 100,000,000 |
| Issued subscribed & fully paid up | | |
| Equity shares | | |
| 95,10,000 Shares @ Rs. 10/- each par value | 95,100,000 | 95,100,000 |
| TOTAL | 95,100,000 | 95,100,000 |

a) Reconciliation of the number of shares

| Particulars | 31.03.2024 | | 31.03.2023 | |
|--|------------------|-------------------|------------------|-------------------|
| | Number | Amount | Number | Amount |
| Shares outstanding at the beginning of the year | 9,510,000 | 95,100,000 | 9,510,000 | 95,100,000 |
| Shares Issued during the year | | | | |
| Shares outstanding at the end of the year | 9,510,000 | 95,100,000 | 9,510,000 | 95,100,000 |

b) Shareholders holding more than 5% shares in the Company

| Particulars | 31.03.2024 | | 31.03.2023 | |
|---|------------|--------------|------------|--------------|
| | Number | % of Holding | Number | % of Holding |
| 1) Shilpa Medicare Ltd (Refer note below) | 9,510,000 | 99.99% | 9,510,000 | 100.00% |

Note:

01 share is held by Ramakant Innani in the representative capacity on behalf of Shilpa Medicare Limited.

c) Shares held by promoters as at

| Promoter Name | 31.03.2024 | | | 31.03.2023 | | |
|------------------------|--------------|------------------|--------------------------------|--------------|--------------|------------------|
| | No of Shares | %Of total shares | % of Change during the year*** | No of Shares | No of Shares | %of total shares |
| 1) Shilpa Medicare Ltd | 9,510,000 | 100% | 0% | 9,510,000 | 9,510,000 | 0% |

As per our Report of even dated
For Bohara Bhandari Bung and Associates LLP
Chartered Accountants
Firm Regn No. 008127S/S200013

For and on behalf of the Board of Directors of
Vegil Labs Private Limited

Sd/-

CA. Yogesh R.Bung
Partner
M.No. 143932
Place : Raichur
Date : 22/05/2024

Sd/-

Vishnukanth Bhutada
DIN No.01243391
Director
Place : Raichur
Date : 22/05/2024

Sd/-

Ramakant Innani
DIN No.03222748
Director

NOTES TO THE FINANCIAL STATEMENTS

CORPORATE INFORMATION

Vegil Labs Private Limited is a Private Limited Company incorporated on 30/06/2021, with its registered office at 12-6-214/A-1, Shilpa House Hyderabad Road, RAICHUR -584135 Karnataka. Presently, the Company is engaged in the business of Biotechnology using sophisticated technology meticulously in order to comply with laid down international standards/specifications. The company is also engaged in making investments in other companies.

1. Basis of Preparation

a) Statement of Compliance

These Consolidated financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) as specified under section 133 of the Companies Act 2013 read together with the Rule 4 of Companies (Indian Accounting Standards) Rules, 2015 as amended by Companies (Indian Accounting Standards) Amendment Rules 2016 to the extent applicable and the other relevant provisions of the Act, pronouncements of the regulatory bodies applicable to the Group.

These financial statements have been prepared by The Group as a going concern on the basis of relevant Ind AS that are effective or elected for early adoption at The Group's annual reporting date March 31, 2024. The accounting policies are applied consistently to all the periods presented in the financial statements. The Consolidated financial statements of The Group for the year ended March 31, 2024 were approved by the Board of Directors on May 22, 2024.

b) Principles of consolidation

These consolidated financial statements relates to Vegil Labs Private Limited ('The Group'), and its Joint Venture ("the Group"). These consolidated financial statements have been prepared on the following basis:

Investment in Associates and Joint Ventures has been accounted under the equity method as per Ind AS 28.

The Group accounts for its share in post-acquisition changes in net assets of associates and joint ventures, after eliminating unrealized profits and losses resulting from transactions between The Group and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss, to the extent such change is attributable to the associates Statement of Profit and Loss and through its reserves for the balance based on available information.

a) The Joint ventures considered in the preparation of consolidated Financial Statements for the previous year are as under:

| SL No. | Name of the Joint Ventures | Country | Extent of holding |
|---------------|--|----------------|--------------------------|
| 1 | Sravathi AI Technology Private Limited | India | 55% |
| 2 | Auxilla Pharmaceuticals & Research LLP | India | 40% |

c) Functional and Presentation currency

These Consolidated financial statements are presented in Indian rupees (INR), which is also the functional currency of The Group. All amounts have been rounded-off to the nearest thousands, unless otherwise indicated.

d) Basis of Measurement

The Consolidated financial statements have been prepared on the historical cost basis (i.e. on accrual basis), except for the following assets and liabilities which have been measured at fair value wherever applicable

- Certain financial assets / liability measured at fair value,
- Net defined benefit assets/(liability) are measured at fair value of plan assets, less present value of defined benefit obligations.

e) Critical accounting Estimates and Judgements:

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Revisions to accounting estimates are recognised prospectively. The changes in the estimates are reflected in the Consolidated financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the Consolidated financial statements.

The areas involving critical estimates or judgments are:

- Recognition of deferred taxes (Note 1.1(e))
- Provision for income taxes and related tax contingencies. (Note 1.1(e))
- Estimation of provision and contingent liabilities (Note 1.1(d))

1.1 Material Accounting Policies

a) Investments in subsidiaries, joint ventures and associates measured at cost - non-current

Investments in Subsidiaries, Joint ventures and Associates are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in Subsidiaries, Joint ventures and Associates, the difference between net disposal proceeds and the carrying amounts are recognised in the statement of profit and loss.

b) Revenue Recognition:

Revenue is recognized to the extent that it is probable that the economic benefits will flow to The Group and the revenue can be reliably measured.

(i) Other Income

- i. Interest Income is recognized using the Effective interest rate (EIR) method.

c) Financial Instrument:

A financial instrument is any contract that gives rise to a financial asset of one entity and financial liability or equity instrument of another entity.

(I) Financial Asset:

Initial recognition and measurement

All financial instruments are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through P&L, transaction costs that are attributable to the acquisition of the financial asset, purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place are recognized on the trade date i.e. the date that The Group commits to purchase or sell the asset.

Subsequent Measurement

For the purpose of subsequent measurement financial assets are classified as measured at:

- Amortised cost
- Fair value through profit and loss (FVTPL)
- Fair value through other comprehensive income (FVOCI).

(a) Financial Asset measured at amortized cost

Financial Assets held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding are measured at amortized cost using effective interest rate (EIR) method. The EIR amortization is recognized as finance income in the statement of Profit & Loss. The Group while applying above criteria has classified the following at amortized cost:

- (a) Trade receivables
- (b) Loans
- (c) Other financial assets

(b) Financial Assets Measured at fair value through other comprehensive income

Financial assets that are held within a business model whose objective is achieved by both, selling financial assets and collecting contractual cash flows that are solely payments of principal and interest, are subsequently measured at fair value through other comprehensive income. Fair value movements are recognized in the other comprehensive income (OCI). Interest income measured using the EIR method and impairment losses, if any are recognized in the Statement of Profit and Loss. On derecognition, cumulative gain or loss previously recognised in OCI is reclassified from the equity to 'other income' in the Statement of Profit and Loss.

(c) Financial Assets at fair value through profit or loss (FVTPL)

Financial Asset are measured at Fair value through Profit & Loss if it does not meet the criteria for classification as measured at amortized cost or at FVTOCI. All fair value changes are recognized in the statement of Profit & Loss.

Equity Instruments

All investments in equity instruments classified under financial assets are initially measured at fair value, the group may, on initial recognition, irrevocably elect to measure the same either at FVOCI or FVTPL.

De-recognition of Financial Assets:

Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire or the financial asset is transferred and the transfer qualifies for Derecognition. On Derecognition of a financial asset in its entirety, the difference between the carrying amount (measured on the date of recognition) and the consideration received (including any new asset obtained less any new liability assumed) shall be recognized in the statement of Profit & Loss.

Impairment of Financial Assets:

In accordance with Ind AS 109, The Group applies expected credit loss (ECL) model by adopting the simplified approach using a provision matrix reflecting current condition and forecasts of future economic conditions for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- (a) Financial Assets that are debt instruments, and are measured at amortized cost e.g. loans, debt securities, deposits, trade receivables and bank balance
- (b) Financial Assets that are debt instruments and are measured at FVTOCI.
- (c) Lease receivables under Ind AS 17.
- (d) Trade receivables or any contractual right to receive cash or another financial asset
- (e) Loan commitments which are not measured at FVTPL
- (f) Financial guarantee contracts which are not measured at FVTPL

(II) Financial Liability

Initial recognition and measurement

Financial liabilities are recognized initially at fair value plus any transaction cost that are attributable to the acquisition of the financial liability except financial liabilities at FVTPL that are measured at fair value.

Subsequent measurement

Financial liabilities are subsequently measured at amortised cost using the EIR method. Financial liabilities carried at fair value through profit or loss are measured at fair value with all changes in fair value recognised in the Statement of Profit and Loss.

Financial Liabilities at amortized cost:

Amortized cost for financial liabilities represents amount at which financial liability is measured at initial recognition minus the principal repayments, plus or minus the cumulative amortization using the effective interest method of any difference between the initial amount and the maturity amount.

The Group is classifying the following under amortized cost

- Borrowings from banks
- Borrowings from others
- Other Financial Liabilities

Derecognition:

A financial liability shall be derecognized when, and only when, it is extinguished i.e. when the obligation specified in the contract is discharged or cancelled or expires.

d) Taxes on Income:

Income tax comprises of current and deferred income tax. Income tax expense is recognised in statement of profit and loss except to the extent that it relates to an item recognised directly in equity in which case it is recognised in other comprehensive income. Current income tax for current year and prior periods is recognised at the amount expected to be paid or recovered from the tax authorities, using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis.

Deferred tax is recognised in respect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Deferred income tax assets and liabilities are measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognised as income or expense in the period that includes the enactment or substantive enactment date. A deferred income tax assets is recognised to the extent it is probable that future taxable income will be available against which the deductible temporary timing differences and tax losses can be utilised. The

Group offsets income-tax assets and liabilities, where it has a legally enforceable right to set off the recognised amounts and where it intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

e) Provisions, Contingent Liabilities and Contingent Assets

A provision is recognised when The Group has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. If effect of the time value of money is material, provisions are discounted using an appropriate discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of The Group or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. The Group does not recognize a contingent liability but discloses its existence in the Consolidated financial statements

f) Borrowing Cost

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are recognized as an expense in the period in which they are incurred. Further, interest earned out of borrowed funds from temporary investments are reduced from the borrowing cost.

Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

g) Earnings per share

The Group presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding during the period.

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.

h) Cash Flow Statements

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Group are segregated.

i) Cash and Cash Equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand, short-term deposits and other short-term highly liquid investments with an original maturity of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

For the purposes of the presentation of cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft as they being considered as integral part of the Group's cash management system.

j) Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the Consolidated balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

k) Exceptional Items:

Exceptional items refer to items of income or expense within the statement of profit and loss from ordinary activities which are non-recurring and are of such size, nature or incidence that their separate disclosure is considered necessary to explain the performance of The Group.

l) Recent accounting developments

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Group.

Vegil Labs Private Limited*(All amounts are in Indian Rupees unless otherwise stated)***Financial Assets****2 Investments**

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|-------------------|--------------------|
| <u>Other Investments</u> | | |
| <u>a) Investment in Associates</u> | | |
| i) Capital contribution in Auxilla Pharmaceuticals & Research LLP(40%) | - | 43,151,841 |
| i) In 55,000 (55,000) equity shares of Rs 10/- each - in Sravathi AI Technology Pvt Ltd , Bangalore | 550,000 | 550,000 |
| Deemed Investments in Sravathi AI Technologies Pvt Ltd | 9,920,858 | 10,226,320 |
| <u>b) Investments in Preference Instruments (Unquoted)</u> | | |
| 9,00,000 (P.Y 751750) Non Cumulative compulsory Convertible share of Rs. 100/- each of Sravathi AI Technology Pvt Ltd Bangalore | 49,217,292 | 48,437,672 |
| Total | 59,688,149 | 102,365,833 |

3 Loans

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|-------------------|------------------|
| Unsecured Loan To | | |
| 1) Shilpa Medicare Ltd | 65,059,072 | - |
| <u>Terms of repayment</u> | | |
| Term loan to Holding company is re-payable over a period of 8 years including moratorium of 5 years. The re-payment will made in 12 Quarterly installments including interest accrued there on. | | |
| <u>Rate of Interest</u> | | |
| Interest is charged at 7.5 % per annum | | |
| Total | 65,059,072 | - |

4 Other Financials Assets

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|--------------------------------------|------------------|------------------|
| 1) Interest accrued but not received | 702,421 | - |
| Total | 702,421 | - |

5 Other non-current assets

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|-------------------|------------------|------------------|
| 1) TDS Receivable | 78,047 | - |
| Total | 78,047 | - |

Vegil Labs Private Limited*(All amounts are in Indian Rupees unless otherwise stated)***6 Deferred Tax Assets / (Liabilities)**

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|------------------|------------------|
| 1) Deferred tax Liabilities (On account of timing difference in recognition of notional income on fair valuation of investments in Sravathi AI Technology Pvt Ltd) | (1,369,597) | (898,185) |
| 2) Deferred tax Assets (On account of losses under Income tax act,1961 & others) | 2,777,647 | 275,734 |
| Total | 1,408,050 | (622,450) |

7 Cash and Cash Equivalents

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|--|------------------|------------------|
| a) Balance with banks in current account | 66,920 | 27,116 |
| Total | 66,920 | 27,116 |

9 Other Equity

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|-------------------------------------|-------------------|---------------------|
| a) Retained Earnings | | |
| Opening Balance | (22,390,693) | (996,524) |
| Add: Profit / (Loss) for the Period | 54,001,180 | (21,394,169) |
| Total | 31,610,486 | (22,390,693) |

10 Borrowings

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|------------------|-------------------|
| Unsecured Loan from | | |
| 1) Shilpa Medicare Ltd | - | 28,025,000 |
| Terms of repayment | | |
| Term loan from Holding company is re-payable over a period of 8 years including moratorium of 5 years. The re-payment will made in 12 Quarterly installments including interest accrued there on. | | |
| Rate of Interest | | |
| Interest is charged at 7.5 % per annum | | |
| Total | - | 28,025,000 |

Vegil Labs Private Limited*(All amounts are in Indian Rupees unless otherwise stated)***11 Other Financial Liabilities**

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|------------------|------------------|
| a) Interest accrued but not due on borrowings | - | 916,373 |
| Total | - | 916,373 |

12 Other Current Liability

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|----------------------------|------------------|------------------|
| a) Tax deduction at source | 229,173 | 101,819 |
| Total | 229,173 | 101,819 |

13 Provision

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|----------------------------|------------------|------------------|
| a) Provision For Audit Fee | 63,000 | 18,000 |
| Total | 63,000 | 18,000 |

14 Other Income

| Particulars | For the Year ended 31.03.2024 | For the Year ended 31.03.2023 |
|---|-------------------------------|-------------------------------|
| a) Notional Income on FV of Preference Shares | 5,441,820 | 3,454,557 |
| b) Interest Received on USL / Delay in Sale Consideration | 1,780,468 | - |
| Total | 7,222,288 | 3,454,557 |

15 Finance Cost

| Particulars | For the Year ended 31.03.2024 | For the Year ended 31.03.2023 |
|-------------------------------|-------------------------------|-------------------------------|
| a) Interest on Unsecured loan | 2,221,728 | 1,018,192 |
| Total | 2,221,728 | 1,018,192 |

16 Other Expenses

| Particulars | For the Year ended 31.03.2024 | For the Year ended 31.03.2023 |
|---|-------------------------------|-------------------------------|
| a) Rates & Taxes | 5,200 | 7,900 |
| b) Payment to Auditors (Refer Note No.13) | 75,000 | 29,000 |
| c) GST written off | 4,140 | 4,680 |
| d) Bank Charges | 1,037 | 745 |
| Total | 85,377 | 42,325 |

Vegil Labs Private Limited*(All amounts are in Indian Rupees unless otherwise stated)***17 Payment to Statutory Auditors ***

| Particulars | As at 31.03.2024 | As at 31.12.2023 |
|-----------------------|-------------------------|-------------------------|
| a) Statutory Audit | 30,000 | 15,000 |
| b) Limited Review | 15,000 | 9,000 |
| c) Income Tax matters | 30,000 | 5,000 |
| Total | 75,000 | 29,000 |

18 Earning per share

| Particulars | As at 31.03.2024 | As at 31.12.2023 |
|--------------------------------------|-------------------------|-------------------------|
| Earning per share | | |
| Net Profit after taxes | 54,001,180 | (21,394,169) |
| Weighted Average No of Equity shares | 9,510,000 | 9,510,000 |
| Face Value | 10.00 | 10.00 |
| Basic & Diluted EPS | 5.68 | (2.25) |

Vegil Labs Private Limited*(All amounts are in Indian Rupees , Except Shares data and per Share data, unless otherwise stated)***19 Analytical ratio**

| SI No | Particular | Numerator | Denominator | 31st March 2024 | 31st March 2023 | Variation % | Reasons for variance of above 25% |
|-------|---|--------------------------------------|--|-----------------|-----------------|-------------|--|
| 1 | Current Ratio(in times) | Current Assets | Current Liabilities | 0.23 | 0.23 | 1.21% | NA |
| 2 | Debt Equity Ratio(in times) | Total Debt | Share holder equity | - | 0.39 | -100.00% | Decrease is mainly on account of full repayment of loan from holding company during the year |
| 3 | Debt service coverage ratio(in times) | Earnings available for debt service | Debt service | - | 0.12 | -100.00% | Decrease is mainly on account of full repayment of loan from holding company during the year |
| 4 | Inventory turnover ratio(in times) | Sales | Average inventory | - | - | - | Not Applicable |
| 5 | Return on equity(in %) | Net profit after taxes | Average shareholders equity | 0.54 | (0.29) | -284.06% | Increase mainly on account of exceptional gain on account of sale of stake in Auxilla Pharmaceuticals & Research LLP |
| 6 | Trade receivable turnover ratio(in times) | Revenue | Average Trade Receivables | - | - | - | Not Applicable |
| 7 | Trade payable turnover ratio(in times) | Purchase for trade and services | Average Trade Payables | - | - | - | Not Applicable |
| 8 | Net Capital turnover ratio(in times) | Revenue | Working Capital | - | - | - | Not Applicable |
| 9 | Net Profit ratio(in %) | Net Profit | Revenue | - | - | - | Not Applicable |
| 10 | Return on Capital Employed(%) | Earning Before Interest and Tax | Capital Employed | 5.63% | 3.37% | 67.31% | Increase is mainly on account of full repayment of loan from holding company during the year |
| 11 | Return on investment (in %) | Income generated from invested funds | Average invested funds in treasury investments | | | - | Not Applicable |

Vegil Labs Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

20 Related Party Transactions

Related parties where control exists and related parties with whom transactions have taken place are listed below:

1 Holding Company

- a) Shilpa Medicare Limited

2 Enterprises having common control

- a) Shilpa Pharma Lifesciences Ltd
b) Auxilla Pharmaceuticals & Research LLP
c) Sravathi AI Technology Pvt Ltd

| SL No | Name of related Party | Descriptions of Transaction | 2023-24 | | 2022-23 | |
|---------------------------------|--|---|--------------------------------------|-----------------------|--------------------------------------|-----------------------|
| | | | Income/ (expenses) other transaction | Balance at 31.03.2024 | Income/ (expenses) other transaction | Balance at 31.03.2023 |
| i | Shilpa Medicare Limited | Reimbursement of Expenses | (101,819) | - | 1,800 | - |
| | | Share Application excess returned | - | - | (150,000) | - |
| | | Received during the year | (15,000,000) | - | - | 28,025,000 |
| | | Loan Repaid during the Year | 43,941,373 | - | - | - |
| | | Closing balance during the year | - | - | - | 28,025,000 |
| | | Maxmium Loan outstanding during the year | - | 43,941,373 | - | 28,025,000 |
| | | Interest on Loan (expenses) | (2,221,728) | - | (1,018,192) | (916,373) |
| | | <u>Loan advanced</u> | | | | |
| | | Given during the year | 67,058,627 | - | - | - |
| | | Repaid during the year | - | - | - | - |
| Closing balance during the year | - | 65,059,072 | - | - | | |
| | | Maxmium Loan outstanding during the year | - | - | - | - |
| | | Interest on Loan (Income) | 780,468 | 702,421 | - | - |
| iii | Auxilla Pharmaceuticals & Research LLP | Investment | - | - | - | 46,352,035 |
| | | Sale Consideration received | 110,000,000 | - | - | - |
| | | Interest received on delay in payment of Sale Consideration | 1,000,000 | - | - | - |
| iv | Sravathi AI Technology Pvt Ltd | Investment in Equity Shares | - | 550,000 | - | 550,000 |
| | | Investment in Preference shares | 14,825,000 | 59,138,149 | 31,075,000 | 58,663,992 |

a) The Above disclousers include related parties as per Ind AS 24 on " Related Party Disclousers" and Companies Act,2013.

Vegil Labs Private Limited*(All amounts are in Indian Rupees unless otherwise stated)***21 Fair value measurement hierarchy**

| Particulars | FVTPL | FVTOCI | Amortised cost | Total |
|--|------------|----------|--------------------|--------------------|
| 31.03.2024 | | | | |
| Non-current Assets | | | | |
| Investments | 9,920,858 | - | 49,767,292 | 59,688,149 |
| Loans | - | - | 65,059,072 | 65,059,072 |
| Current Financial Assets | | | | |
| Cash & Bank Balance | - | - | 66,920 | 66,920 |
| Trade Receivable | - | - | - | - |
| Total | - | - | 114,893,283 | 124,814,141 |
| Non-Current Financial Liability | | | | |
| Borrowings | - | - | - | - |
| Current Financial Liability | | | | |
| Trade payables | - | - | - | - |
| Other financial liabilities | - | - | - | - |
| Total | - | - | - | - |
| 31.03.2023 | | | | |
| Non-current Assets | | | | |
| Investments | 59,213,992 | - | 43,151,841 | 102,365,833 |
| Loans | - | - | - | - |
| Current Financial Assets | | | | |
| Cash & Bank Balance | - | - | 27,116 | 27,116 |
| Trade Receivable | - | - | - | - |
| Total | - | - | 43,178,957 | 102,392,949 |
| Non-Current Financial Liability | | | | |
| Borrowings | - | - | 28,025,000 | 28,025,000 |
| Current Financial Liability | | | | |
| Trade payables | - | - | - | - |
| Other financial liabilities | - | - | 916,373 | 916,373 |
| Total | - | - | 916,373 | 916,373 |

Fair value hierarchy

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consist of the following three levels:

- Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 — Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 — Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

22 Financial Risk Management

The group's activities expose it to a variety of financial risks such as Market Risk, Credit Risk and Liquidity Risk. The group focuses on minimizing potential adverse effect on its financial performance.

(i) Foreign Currency Risk

The group does not operate internationally, hence, it is not exposed to foreign currency risk.

(ii) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of the financial instruments will fluctuate because of changes in market interest rates. In order to optimize The group's position with regards to interest expenses/ income and to manage the interest rate risk, The group weighted average balance manage its interest rate risk by having portfolio of fixed / variable interest rate on long / short term borrowings. The analysis is prepared assuming the amount of liability outstanding at the ending of the reporting period is the average weighted balance of the respective reporting period.

The group does not have borrowings with floating interest rate, it is not exposed to interest rate risk.

(ii) Price Risk

The group does not have any exposure to price risk ,as there is no market based equity investment made by The group.

(iv)Liquidity risk

Liquidity risk is the risk that The group will encounter difficulty in meeting the obligations of its financial liability.The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for making payment towards liability when they are due, under normal and stressed condition without incurring losses and risk. The present available working capital facility is sufficient to meet its current requirement. Accordingly no liquidity risk is perceived.

Maturity Profile of Financial Liabilities as on March 31, 2024

| Particulars | On Demand | < 01 Year | 01 to 5 Years | > 05 Year |
|---------------------------------|-----------|-----------|---------------|-----------|
| (i) Other financial liabilities | - | - | - | - |
| (ii) Borrowings | - | - | - | - |
| Total | - | - | - | - |

Maturity Profile of Financial Liabilities as on March 31, 2023

| Particulars | On Demand | < 01 Year | 01 to 5 Years | > 05 Year |
|---------------------------------|-----------|----------------|---------------|-------------------|
| (i) Other financial liabilities | - | 916,373 | - | - |
| (ii) Borrowings | - | - | - | - |
| | - | - | - | 28,025,000 |
| Total | - | 916,373 | - | 28,025,000 |

23 Capital Management

The group's objectives when managing capital are to:

i) Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders.

ii) Maintain an optimal capital structure to reduce the cost of capital.

Consistent with others in the industry, The group monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings net of cash and cash equivalents) divided by total 'equity' (as shown in the balance sheet)

| Particulars | 31-Mar-24 | 31-Mar-23 |
|--------------------------|-------------|-------------|
| Net Debt | - | 28,025,000 |
| Total Equity | 126,710,486 | 72,709,307 |
| Debt Equity Ratio | - | 0.39 |

24 Reconciliation Of Tax Expenses**(i) Income Tax**

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|--|-------------------|---------------------|
| Statement of Profit or loss | 53,352,130 | (20,771,719) |
| Current Tax | - | - |
| Deferred Tax | (649,049) | 622,450 |
| Amount recognised in statement of profit & loss acco | (649,049) | 622,450 |
| Profit/(Loss) before tax from continuing operation after exceptional item | 53,352,130 | (20,771,719) |
| Tax at enacted tax rate in India C.Y. @ 25.168% (P.Y. 25.168 %) | 13,427,664 | (5,227,826) |
| Effect of: | | |
| Exempt Income | (16,764,856) | - |
| Others | 2,688,143 | 5,850,276 |
| | (649,049) | 622,450 |

Recognised Deferred Tax Assets / Liabilities

| Particulars | As at 31.03.2024 | As at 31.03.2023 |
|---|--------------------|------------------|
| Opening Balance | (622,450) | - |
| Deferred Tax Liability in relation to: | - | - |
| Property, plant and equipment, and intangible assets | - | - |
| Fair value of Pref Share Liabilities through PL A/c | (1,369,597) | (898,185) |
| Fair valuation of Leases Liability through PL A/c (Net) | - | - |
| Deferred Tax Liability | (1,369,597) | (898,185) |

| Deffered Tax Asset in relation to; | | |
|---|------------------|------------------|
| Loss as per IT Act | 2,777,647 | 275,734 |
| Liabilities FV through PL A/c | - | - |
| Other disallowable expenses | - | - |
| Deffered Tax Asset | 2,777,647 | - |
| Net Deferred Tax (Liability) / Asset | 1,408,050 | (622,450) |

25 Additional Regulatory information

25.01 Title deeds of immovable properties

The group does not hold any immovable properties during the year.

25.02 Loans or advances to specified persons

No loans or advances in the nature of loans are granted to promoters, directors, KMPS and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are repayable on demand or without specifying any terms or period of repayment.

25.03 Details of benami property held

No proceedings have been initiated on or are pending against The group for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.

25.04 Wilful defaulter

The group has not been declared wilful defaulter by any bank or financial institution or other lender.

25.05 Relationship with struck off companies

The group has no transactions with the companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956.

25.06 Registration of charges or satisfaction with Registrar of Companies (ROC)

There are no charges or satisfaction yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

25.07 Compliance with number of layers of companies

The group has complied with the number of layers prescribed under the Section 2(87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rules, 2017.

25.08 Undisclosed income

There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded previously in the books of account.

25.09 Details of crypto currency or virtual currency

The group has not traded or invested in crypto currency or virtual currency during the current or previous year.

25.10 Utilisation of borrowings availed from banks and financial institutions

No funds have been advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) by The group to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the intermediary shall lend or invest in party identified by or on behalf of The group (Ultimate Beneficiaries). The group has not received any fund from any party(s) (Funding Party) with the understanding that The group shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of The group ("Ultimate Beneficiaries") or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

25.11 Valuation of PP&E, intangible asset and investment property

As the group is not holding any PPE, Intangible Assets or investment property both in the current and previous year disclosure under this clause is not applicable.

26 Previous year figures have been regrouped / reclassified/ rearranged wherever necessary to correspond with current year classification / disclosure.

The accompanying significant accounting policies and notes form an integral part of the financial statements.

As per our Report of even dated
for Bohara Bhandari Bung & Associates LLP
Chartered Accountants
Firm's registration No.008127S/S200013

For and on behalf of the Board of Directors of
Vegil Labs Private Limited

Sd/-

Sd/-

Sd/-

CA. Yogesh R.Bung
Partner
M.No.143932

Vishnukanth Bhutada
Director
DIN No.01243391

Ramakant Innani
Director
DIN No.03222748

Place : Raichur
Date : 22/05/2024

Place : Raichur
Date : 22/05/2024